Cancer
Conditions
Keywords
Next-generation sequencing (NGS), Cost, Cancer diagnosis
Brief summary
The aim of this study was to measure the total cost of performing next-generation sequencing (NGS) in clinical practice in France, in both germline and somatic cancer genetics. The study was performed on 15 French representative cancer molecular genetics laboratories performing NGS panels' tests. The production cost was estimated using a micro-costing method with resources consumed collected in situ in each laboratory from a healthcare provider perspective. A top-down methodology for specific post-sequencing steps was used. Additional non-specific costs were also included and costs were detailed per step of the process.
Interventions
OTHERMeasure of the total cost of performing next-generation sequencing (NGS)
Resources consumed were collected for each laboratory using a standardized questionnaire. The production costs were calculated for the overall process and resources consumed for each step were identified.
Sponsors
Fondation Ophtalmologique Adolphe de Rothschild
Study design
Observational model
OTHER
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Healthy volunteers
Yes
Inclusion criteria
* French genetics laboratories performing somatic and germline clinical NGS tests.
Exclusion criteria
\-
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Overall production cost | through study completion, an average of 5 years | The study is performed on 15 French representative cancer molecular genetics laboratories performing NGS panels' tests. The production cost is estimated using a micro-costing method with resources consumed collected in situ in each laboratory from a healthcare provider perspective. A top-down methodology for specific post-sequencing steps is used. |
Outcome results
None listed